TY - JOUR
T1 - Impact of long-acting therapies on the global HIV epidemic
AU - Chandiwana, Nomathemba C.
AU - Serenata, Celicia M.
AU - Owen, Andrew
AU - Rannard, Steve
AU - Casas, Carmen Perez
AU - Scott, Cherise
AU - Hill, Andrew
AU - Clayden, Polly
AU - Flexner, Charles
N1 - Funding Information:
NC has received research funding from ViiV Healthcare, Merck, Janssen and Gilead, and speaker fees from Janssen.
Funding Information:
A.O. and S.R. thank Unitaid for co-funding creation of CELT and for project LONGEVITY. A.O. and S.R. are Directors of Tandem Nano Ltd and co-inventors, with C.F., of patents relating to drug delivery for infectious diseases. A.O. has received research funding from ViiV Healthcare, Merck, Janssen and consultancy from Gilead, ViiV Healthcare and Merck. C.F. has served as a paid consultant to Merck, Mylan Pharmaceuticals, and ViiV Healthcare; is a paid Data Safety and Monitoring Board member for Algernon Pharmaceuticals; and has served as an expert witness in a legal case involving Gilead Sciences.
Funding Information:
Funding for this AIDS journal supplement was provided by the US Agency for International Development (USAID) through the OPTIMIZE Cooperative Agreement AID-OAA-A-15-00069 to Ezintsha, University of the Witwatersrand. The content of this supplement is solely the responsibility of the authors and does not necessarily represent the official views of USAID, or any other agency.
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/12/15
Y1 - 2021/12/15
N2 - Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current dailybased oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.
AB - Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may improve dosing convenience, tolerability and cost compared with current dailybased oral therapy. They can also circumvent stigma associated with oral therapy for both treatment and PrEP, thereby improving adherence and outcomes. Yet, multiple challenges remain, many specific to low-income and middle-income countries (LMICs), where the epidemic is most concentrated and HIV prevention and treatment options are limited. To optimize the use of long-acting formulations, key outstanding questions must be addressed. Uncertain costing, scale-up manufacturing, complex delivery systems and implementation challenges are potential barriers when considering the scalability of long-acting ARVs for global use.
KW - Access and barriers
KW - Long-acting antiretrovirals
KW - Low-income and middle-income countries
KW - Treatment optimization
UR - http://www.scopus.com/inward/record.url?scp=85120538209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120538209&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003102
DO - 10.1097/QAD.0000000000003102
M3 - Article
C2 - 34848580
AN - SCOPUS:85120538209
SN - 0269-9370
VL - 35
SP - S137-S143
JO - AIDS
JF - AIDS
IS - Supplement 2
ER -